Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02831257 | AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | PHASE2 | COMPLETED | 18 | — | — | Aug 31, 2016 | Oct 1, 2020 | Jun 13, 2022 | 2 | United States |
Number of Target Meningiomas with a Decrease in Tumor Volume of at least 20% Compared with Baseline
| Arm | Type | Description |
|---|---|---|
| AZD2014 | EXPERIMENTAL | 18 patients will be enrolled in this study in a single stage. * AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days. * One cycle will consist of 28 days (1 cycle = 28 days). |
| Name | Type | Description |
|---|---|---|
| AZD2014 | DRUG | - |
Inclusion Criteria: * Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling National Institute of Health (NIH) criteria or Manchester criteria, or by detection of a causative mutation in the NF2 gene. * Participants must have progressive or symptomatic meningioma. NOTE 1: Hi...